Comparison of Procedure (PRP) with Medicine (Topical Minoxidil) in the treatment of hair loss.

Comparison of effectiveness of Platelet-Rich-Plasma (PRP) Therapy With and Without Topical Minoxidil 5% in Patients with Androgenetic Alopecia: A Randomized Controlled Trial - PRISMA-MIND

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/053205

Enrollment

Registered

2023-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: Platelet-Rich-Plasma (PRP) with Topical Minoxidil 5%: PRP is a less invasive surgical procedure which enhances hair growth by providing platelet-rich in growth factors. Dose: NA Freque

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with male type-baldness of Hamilton–Norwood scale II–V and female pattern baldness of Ludwig scale II-III. 2. Within the age group of 18–60 years. 3. Not using topical minoxidil and oral/topical finasteride for at least 6 months before the start of study 4. Patients providing consent.

Exclusion criteria

Exclusion criteria: 1. Patients with inflammation or erythema (except mild seborrheic dermatitis), or scarring over the scalp. 2. Patients on anticoagulants, antihypertensives, anticonvulsants, aspirin, or other nonsteroidal anti-inflammatory drugs. 3. Patients with previous history or current malignancies, platelet or bleeding disorders, bone marrow aplasia, diabetes, HIV, hepatitis B or C infection or immunocompromised patients, and those having a propensity for keloids.

Design outcomes

Primary

Measure	Time frame
1. Change of Hair density from baseline by dermascopic pictures 2. Change of Target Area Hair Count (TAHC) from baseline 3. Clinical Photographs 4. Change from baseline Target Area Hair Width (TAHW) 5. Change from baseline Investigator Assessed Score on patient hair growth/loss at the vertex [7-point scale from -3 (Greatly decreased) to +3 (Greatly increased)] 6. Treatment-emergent adverse events (TEAEs)Timepoint: Week 0, 6 and 12	—

Measure

Time frame

1. Change of Hair density from baseline by dermascopic pictures 2. Change of Target Area Hair Count (TAHC) from baseline 3. Clinical Photographs 4. Change from baseline Target Area Hair Width (TAHW) 5. Change from baseline Investigator Assessed Score on patient hair growth/loss at the vertex [7-point scale from -3 (Greatly decreased) to +3 (Greatly increased)] 6. Treatment-emergent adverse events (TEAEs)Timepoint: Week 0, 6 and 12

—

Secondary

Measure	Time frame
Dermatology Life Quality Index (DLQI)Timepoint: Week 0 and 12;Patient Self-Assessment Score Patient assessed their scalp hair on hair growth assessment by following scoring, • 0- No Improvement. • 1- 1-25% Improvement. • 2- 26-50% Improvement. • 3- 51-75% Improvement. • 4- 76-100% Improvement.Timepoint: Week 6 and 12	—

Countries

India

Contacts

Public ContactJoel M Johns

Consultant Dermatologist.

sujayasn@gmail.com9886020078

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026